Menu Back toDIAmond-Session-1

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

DIAmond Session 1: What Do Patients Want for Clinical Trials and Clinical Research? What Should Stakeholders Do?

Session Chair(s)

Naomi  Sakurai

Naomi Sakurai

  • Representative Director
  • Canser Solutions, Co., LTD., Japan
Yoshikata  Furuya, MSc

Yoshikata Furuya, MSc

  • Manager, General Affairs Division
  • Sankeien Hoshoukai Foundation, Japan
Patient and Public Involvement (PPI) in drug developments is increasingly attracting interest in Japan. DIA has organized sessions on PPI at the annual meetings over the past few years to share the concept of PPI and status of PPI in each phase of drug development in Japan and global. In this DIAmond session, leaders of PPI in clinical trials and clinical research will share the latest outcomes and discuss what stakeholders should do to promote PPI in Japan.


Yasuhiro  Fujiwara, MD, PhD

Yasuhiro Fujiwara, MD, PhD

  • Chief Exective
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Agnès  Saint-Raymond, DrMed

Patients’ expectations in Clinical Trials

Agnès Saint-Raymond, DrMed

  • Head of International Affairs Division
  • European Medicines Agency, Netherlands
Kyoko  Imamura, MD, PhD

Promoting Patient and Public Involvement in Japan

Kyoko Imamura, MD, PhD

  • Professor, Social Cooperation Program of IT Healthcare
  • Graduate School of Pharmaceutical Sciences, the University of Tokyo, Japan
Takayuki  Imaeda, MPharm, MS

Patient and Public Involvement (PPI) in drug developments at a pharmaceutical company’s perspective

Takayuki Imaeda, MPharm, MS

  • Senior Director, Regulatory Affairs
  • Pfizer R&D Japan, Japan